ArticleVaccine2025
Different patterns of antimicrobial non-susceptibility of the nasopharyngeal carriage of Streptococcus pneumoniae in areas with high and low levels of PCV13 coverage.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe impact of pneumococcal conjugate vaccines (PCVs) on antimicrobial resistance (AMR) in Streptococcus pneumoniae (Spn) among Chinese children remains inadequately characterized. Evidence is also limited on the interaction between vaccination coverage and regional disparities in AMR patterns. This study aims to assess the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal carriage of Spn and antimicrobial nonsusceptibility to commonly used antibiotics among healthy children under five years of age in China.
methodsIn 2022, 737 pneumococci were isolated from 2333 healthy children recruited in 4 areas (Haikou, Wanning, Baisha, and Qiongzhong) in Hainan Province, China. Serotyping and antimicrobial susceptibility tests were performed. Participants were divided into 4 groups based on individual PCV13 vaccination history and the local vaccination coverage rates: vaccinated and unvaccinated groups in the high-coverage area (group VH & NVH), and vaccinated and unvaccinated groups in the low-coverage areas (group VL & NVL). Descriptive statistics and logistic regression analysis were used to assess the vaccine impacts.
resultsPCV13-vaccinated children exhibited significantly lower carriage rates of vaccine-type serotypes (VTs) compared to unvaccinated children: 6B (7.0 % vs. 2.7 %, P < 0.01), 6A (4.2 % vs. 1.2 %, P < 0.05), and 23F (2.2 % vs. 0.3 %, P < 0.05). The non-susceptibility rates to erythromycin, azithromycin, clindamycin, tetracycline, penicillin, and cefuroxime were 92.3 %, 87.5 %, 81.2 %, 91.2 %, 38.9 % and 64.7 %, respectively, resulting in 82.9 % of isolates being multidrug-resistant (MDR), especially to VTs (92.4 %). Isolates from the high PCV13 coverage area were less resistant to penicillin, cefuroxime, erythromycin, azithromycin, clindamycin and SXT, and were less MDR than isolates from the low PCV13 coverage areas.
conclusionsNasopharyngeal carriage of Spn was highly resistant to common clinical antibiotics. PCV13 vaccination significantly decreased VTs carriage and antimicrobial nonsusceptibility. These results suggest that the widespread use of PCVs is likely to substantially affect NP carriage and antimicrobial nonsusceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.